Revvity Beats Q3, Raises FY2026 Guidance to $5.40-$5.45 Pro Forma Adjusted EPS
RVTY has more than doubled off its 52-week low of $81.22.
Summary
Revvity beat Q3 on revenue and adjusted EPS and raised FY2026 pro forma adjusted EPS guidance to $5.40-$5.45, while filing the first pro forma financials for its up-to-$200M China IDX divestiture.
Key Events · Earnings and Guidance · RVTY
-
Q3 Beat With Margin Expansion
Revenue of $729M vs $699M a year ago; adjusted EPS of $1.38 vs $1.18. Adjusted operating margin rose to 28.7% from 26.1%.
-
FY2026 Guidance Raised
Pro forma revenue of approximately $2.86 billion, ~5% pro forma organic growth, and pro forma adjusted EPS of $5.40-$5.45.
-
China IDX Pro Forma Disclosed
Up to $200M sale signed July 31, 2026, expected to close by end of 2027; pro forma statements include a $55M loss on probable disposition and remove ~$62M of nine-month revenue.
-
Segment Momentum
Life Sciences revenue $380M vs $343M, pro forma organic +9%; Diagnostics $349M vs $356M, pro forma organic +5%.
Analysis · RVTY · Industrial Applications And Services
A clean beat paired with a raised full-year guide is the combination that reprices a large-cap medtech/health-science name, and that is what Revvity delivered. Third-quarter revenue of $729M rose from $699M a year ago, adjusted EPS of $1.38 came in well above $1.18, and adjusted operating margin expanded to 28.7% from 26.1% — margin expansion, not just top-line growth, drove the beat. Management now guides FY2026 pro forma revenue of roughly $2.86 billion, ~5% pro forma organic growth and pro forma adjusted EPS of $5.40-$5.45. The filing also supplies the first pro forma financials for the China IDX divestiture (up to $200M, signed July 31, 2026, expected to close by end of 2027), including a $55M loss on probable disposition, so investors can now model the remaining business. With the stock near its 52-week high, the risk is that expectations were already elevated; the raised guide is the offset.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVTY was trading at $167.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $16.9B. The 52-week trading range was $81.22 to $169.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.